Unapproved New Drugs/Misbranded
Similar Posts
FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
On July 2, 2025, the Food and Drug Administration granted accelerated approval to sunvozertinib (Zegfrovy, Dizal (Jiangsu) Pharmaceutical Co., Ltd.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertioBRS Analytical Services, LLC – 711133 – 09/17/2025
CGMP/Finished Pharmaceuticals/AdulteratedVitalityXtra may be harmful due to hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use VitalityXtra, a product promoted and sold for sexual enhancement on various websites, including www.vitalityvita.com, and possibly in some retail stores.In Response to a Broader FDA Investigation, ByHeart Initiates a Voluntary Recall of Two Batches of Infant Formula
[New York, NY] – ByHeart, a next-generation baby nutrition company, announced today that, out of an abundance of caution, it has chosen to voluntarily recall two batches of ByHeart Whole Nutrition Infant Formula following notification from the U.S. Food and Drug Administration (FDA) of a broader ongFDA Listing of Authorized Generics
FDA Listing of Authorized GenericsClinical Outcome Assessment (COA) Qualification Program: Frequently Asked Questions
CDER Clinical Outcome Assessments (COA) Qualification Program: Frequently Asked Questions (FAQs)